Parabilis Medicines
Parabilis Medicines Raises $305M Series F | Precision Medicine Platform
Parabilis Medicines Closes $305M Series F
Parabilis Medicines, a biotechnology company developing precision medicines, has raised $305 million in Series F funding.
The round was co-led by RA Capital Management, Fidelity, and Janus Henderson Investors.
Key Highlights
- Late-stage biotech funding
- Focus on precision medicine
- Strong institutional backing
Company Overview
Parabilis Medicines is advancing a pipeline of precision medicines targeting genetic drivers of disease, with multiple programs in clinical development.
Company Info
Investors (3)
Share
Related Reports
Armadin Raises $255.5M Series B for Autonomous Security
Armadin raised a $255.5 million Series B co-led by Andreessen Horowitz and Accel to scale its agentic security platform and its research, training, and go-to-market efforts.
Homeward Raises $120M Series D for Cash Offer and Bridge Financing
Homeward raised a $120 million Series D led by Saluda Grade, plus $330 million in asset-backed debt, to expand cash offer and bridge financing for real estate agents.
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free